LaserSight
This article was originally published in The Gray Sheet
Executive Summary
Refractive laser firm raises $16 mil. via investments of $8 mil. each by Dawson Samberg Capital Management Funds and TLC The Laser Center, Inc. -both consisting of 2 mil. shares of preferred stock at $4 each. The firm received an additional $4.3 mil. on June 5 in connection with the sale of Vision Twenty-One stock received last December in connection with that firm's acquisition of two of LaserSight's health care subsidiaries ("The Gray Sheet" Jan. 5, In Brief). Proceeds will be used for expansion of the firm's international presence and for U.S. marketing activities, as well as debt repayment and repurchase of all Series B preferred stock. LaserSight and TLC are collaborating to develop a mobile excimer laser business...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.